Slide 1: Second Quarter 2025 Earnings
Click Here to Edit Title Second Quarter 2025 Earnings July 30, 2025
Slide 2: Cautionary Statement
Cautionary Click Here to Statement Edit Title Cautionary Statement Under the Private Securities Litigation Reform Act; Non-GAAP Measures This presentation contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements ma
Slide 3: 2Q25 Highlights
IDEX Click Here 2Q25toHighlights Edit Title Delivered better than expected results despite macro uncertainty IDEX teams accelerated integrated growth strategies Inconsistent day rate pattern and slower customer decision making impacting second half forecast Stable activity and solid execution across
Slide 4: Platforms Growth Origins & Proven Benefits
ClickPlatforms Growth Here to–Edit Title Origins & Proven Benefits IDEX Health & Science (“IH&S”) Optical Technologies (“OT”) Platform built over 20 years of diligent organic and Constructed over 14 years through organic and inorganic capital deployment inorganic strategic initiatives Recently added
Slide 5: Replicating Platform Success with MSS & Mott
Click Here Replicating to Platform IDEX Edit Title Success with MSS & Mott Previous platform experiences, learnings and successes inform current and future platform builds Materials Science Solutions Leading-edge portfolio of applied materials Leader in design and manufacturing of sintered forming s
Slide 6: Q2 2025 Financial Performance
Q2 Click 2025 Here Financial to Edit Title Performance ($ in millions excl. EPS) Sales Adj. EBITDA Margin* Adj. EPS* Free Cash Flow* +1% Organic* -40 bps —% +25% Organic* FX M&A Y/Y ∆ Sales Growth 1% 1% 5% 7% Organic* orders increased 2% y/y Q2 results above expectations but order pattern choppy 6 *
Slide 7: Q2 2025: Health & Science Technologies
Q2 Click 2025: HereHealth to Edit&Title ($ in millions) Science Technologies Orders Sales Adj. EBITDA Margin Highlights +2% Organic* +4% Organic* -170 bps • Continued strength in Pharma, Space/Defense, and Data Center • Analytical Instrumentation steady with trend towards low single digit growth • S
Slide 8: Q2 2025: Fluid & Metering Technologies
Q2 Click 2025: HereFluid to Edit ($ in millions) & Metering Title Technologies Highlights Orders Sales Adj. EBITDA Margin • Order growth across downstream +7% Organic* -2% Organic* +130 bps energy, agriculture, and municipal water • Chemical, water, energy, ag businesses faced tough y/y comparisons;
Slide 9: Q2 2025: Fire & Safety / Diversified Products
Q2 Click 2025: HereFire to Edit ($ in millions) & Safety Title / Diversified Products Highlights Orders Sales Adj. EBITDA Margin • Fire and Safety continues to benefit from strong OEM demand and strong -7% Organic* +2% Organic* +40 bps adoption of our integrated solutions • Order timing effects acro
Slide 10: 2025 Guidance Summary
2025 Click Here Guidance to Edit Summary Title Full Year Third Quarter Current Guidance Current Guidance Organic Revenue % vs Prior Year* ~1% 2% - 3% Adjusted EBITDA %* 26.5% – 27.0% 26.0% – 26.5% Reported Earnings Per Share $6.30 - $6.44 $1.54 - $1.61 Adjusted Earnings Per Share* $7.85 - $7.95 $1.9
Slide 11: Flexible, Returns-Focused Capital Deployment
Flexible, Click HereReturns-Focused to Edit Title Capital Deployment Growth Investments Maintain Strong Balance Sheet and Return Capital to Shareholders • Focused on organic growth • Financial and strategic flexibility afforded by strong cash generation • Tuck-in M&A to scale and expand critical bus
Slide 12: IDEX Value Drivers
IDEXHere Click ValuetoDrivers Edit Title ORGANIC INORGANIC MARGIN GROWTH GROWTH EXPANSION • Leading market entitlement • Strong funnel of M&A opportunities • Leading the IDEX Op Model • Pricing execution • Fast growing companies • 8020 • Growth bets prioritization • Disciplined capital deployment •
Slide 13: Appendix
Click Here to Edit Title Appendix
Slide 14: Strategic Acquisition of Micro-LAM
Strategic Click Here Acquisition to Edit Title of Micro-LAM Micro-LAM is a leading designer and manufacturer of custom precision optical components, ultra-precision diamond tools, and laser-assisted machining devices Specialized capabilities that complement and advance IDEX’s Materials Science Sol
Slide 15: Non-GAAP Reconciliations
Click Here to Edit Title Non-GAAP Reconciliations
Slide 16: Organic Sales Reconciliation
Click Here to Edit Title Table 1: Reconciliations of the Change in Net Sales to Organic Sales HST FMT FSDP IDEX Three Months Ended June 30, 2025 Change in net sales 20% (3%) 3% 7% Less: Net impact from acquisitions/divestitures(1) 15% (2%) —% 5% Impact from foreign currency(2) 1% 1% 1% 1% Change in
Slide 17: Reported to Adjusted Gross Profit
Click Here to Edit Title Table 2: Reconciliations of Reported-to-Adjusted Gross Profit and Gross Margin (dollars in millions) Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 Gross profit $ 392.2 $ 366.8 $ 761.1 $ 724.2 Fair value inventory step-up charges — — — 2.5 Adjusted
Slide 18: Reported to Adjusted Net Income and EPS
Click Here to Edit Title Table 3: Reconciliations of Reported-to-Adjusted Net Income Attributable to IDEX and Diluted EPS Attributable to IDEX (in millions, except per share amounts) Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 Reported net income attributable to IDEX $
Slide 19: Reported Net Income to Adjusted EBITDA
Click Here to Edit Title Table 4: Reconciliations of Net Income to Adjusted EBITDA (dollars in millions) Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 Reported net income $ 131.1 $ 141.2 $ 226.5 $ 262.5 Provision for income taxes 38.8 38.0 67.9 71.2 Interest expense - net
Slide 20: Cash Flow to Free Cash Flow
Click Here to Edit Title Table 5: Reconciliations of Cash Flows from Operating Activities to Free Cash Flow (dollars in millions) Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 Cash flows from operating activities $ 161.7 $ 133.6 $ 267.4 $ 290.2 Less: Capital expenditures
Slide 21: Guidance Reconciliations
Click Here to Edit Title Table 6: Reconciliation of Estimated 2025 Change in Net Sales to Change in Organic Sales Guidance(3) Third Quarter 2025 Full Year 2025 Low End High End Low End High End Estimated change in net sales 7% 9% 5% 6% Less: Net impact from acquisitions/divestitures(1) 4% 4% 3% 3% I
Slide 22: Estimated Net Income to Adjusted EBITDA
Click Here to Edit Title Table 8: Reconciliation of Estimated 2025 Net Income to Adjusted EBITDA (dollars in millions) Guidance(2) Third Quarter 2025 Full Year 2025 Low End High End Low End High End Estimated Reported net income $ 116.2 $ 121.8 $ 476.2 $ 487.2 Provision for income taxes 38.3 40.2 14